Technology Appraisal Committee Meeting (Committee A)

**10 Spring Gardens, London SW1A 2BU**

## Minutes: Confirmed

## Date and Time: Tuesday 28 January 2020, 10am – 2.10pm

### Present:

1. Dr Jane Adam (Chair) Present for all notes
2. Dr Brian Shine Present for all notes
3. Dr Alice Turner Present for all notes
4. Dr Khalida Ismail Present for all notes
5. Dr Andrew Champion Present for all notes
6. Dr Justin Daniels Present for all notes
7. Dr Mark Upton Present for all notes
8. Mr Richard Ballerand Present for all notes
9. Dr Rita Faria Present for all notes
10. Dr Roger Whittaker Present for all notes
11. Mr Stephen Sharp Present for all notes
12. Dr Steve Edwards Present for all notes

### In attendance:

* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Marcia Miller, Administrator, NICE, Present for all notes
* Roshni Maisuria, Technical Analyst, NICE, Present for all notes
* Zoe Charles Technical Adviser, NICE, Present for all notes
* Nigel Armstrong, Kleijnen Systematic Reviews, Evidence Review Group, Present for notes 1 to 8
* Nasuh Buyukkaramikli, Kleijnen Systematic Reviews, Evidence Review Group, Present for notes 1 to 8
* Dr Sridhar Chaganti, Clinical Expert, Consultant Haematologist nominated by RCP, Present for notes 1 to 8
* Dr Kate Cwynarski, Clinical Expert, Clinical expert, Consultant Haematologist (Lymphoma) nominated by RCP, Present for notes 1 to 8
* Stephen Scowcroft, Patient Expert, Director of Operations & External Affairs, Lymphoma Action, Present for notes 1 to 8
* Professor Peter Clark, Cancer Drugs Fund, Clinical Lead, Present for all notes

### Non-public attendees:

* Rosalee Mason, Corporate Office, Coordinator, NICE, Present for all notes
* Adam Storrow, Business Analyst, NICE, Present for all notes
* Heidi Livingstone, Public Involvement adviser, NICE, Present for all notes
* Albany Meikle, TA CHTE, NICE, Present for all notes
* Pilar Pinilla-Dominguez, Scientific Advice, NICE, Present for notes 1 to 5

## Notes

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 10 December 2019.

## Appraisal of Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [ID1576]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Roche.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.

	1. Dr Sridhar Chaganti declared a direct non-financial interest as he has attended advisory board meetings for Roche, which were not relevant to the appraisal.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	2. Dr Kate Cwynarski declared a direct financial interest as she has done consultancy, advisory and speaker work for Roche. In addition she has received travel support from Roche for attending conferences.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	3. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team, Dr Sumithra Maheswaran, Mr Stephen Sharp and Mr Richard Ballerand who gave presentations on the clinical effectiveness and cost effectiveness of polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma.
4. The Chair explained that “representatives” of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

### Part 2a – Closed session (members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
3. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

### Part 2 – Closed session (experts and the company were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Next Technology Appraisal (Committee A) Meeting: Tuesday 25 February 2020, 10am at NICE, 10 Spring Gardens, London, SW1A 2BU.